Chemokine biology on immune checkpoint-targeted therapies.

The use of antagonistic immune checkpoint-targeted monoclonal antibodies has profoundly modified the standard of care and significantly increased the survival for many cancers. However, many patients still do not respond to those treatments. Biomarkers predictive for efficacy or failure of such immunotherapies would allow developing treatment stratification strategies which could further increase the survival rates of patients with cancer. Chemokines are a subset of the immune cell messenger molecules known as cytokines. Chemokines are key chemoattractant molecules which are essential for the homing of immune cells, notably within tumours. Therefore, they are good candidates for providing predictive biomarkers of the clinical response to checkpoint blockade immunotherapies. In this review, we summarise the recent advances in our understanding of the role of chemokines and how chemokine concentrations may set the tone for the efficacy of immune checkpoint-targeted immunotherapies.

• Publication year

  2020

• Venue

  European Journal of Cancer

• Publication date

  2020-08-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ejca.2020.06.009PMID 32823150
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tertiary lymphoid structures improve immunotherapy and survival in melanoma

  2020cited by this paper
• B cells are associated with survival and immunotherapy response in sarcoma

  2020cited by this paper
• Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

  2020cited by this paper
• B cells and tertiary lymphoid structures promote immunotherapy response

  2020cited by this paper
• CXCL1-LCN2 paracrine axis promotes progression of prostate cancer via the Src activation and epithelial-mesenchymal transition

  2019cited by this paper
• Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

  2019cited by this paper
• CCL14 serves as a novel prognostic factor and tumor suppressor of HCC by modulating cell cycle and promoting apoptosis

  2019cited by this paper
• A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis.

  2019cited by this paper
• Peritumoural CCL1 and CCL22 expressing cells in hepatocellular carcinomas shape the tumour immune infiltrate.

  2019cited by this paper
• Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma

  2019cited by this paper
• CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond

  2019cited by this paper
• Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer.

  2019cited by this paper
• Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.

  2019cited by this paper
• A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

  2019cited by this paper
• Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.

  2019cited by this paper
• Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

  2019cited by this paper
• CCL28-induced RARβ expression inhibits oral squamous cell carcinoma bone invasion.

  2019cited by this paper
• Tertiary lymphoid structures in the era of cancer immunotherapy

  2019cited by this paper
• Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Letter

  2018cited by this paper
• Chemokine CCL4 Induces Vascular Endothelial Growth Factor C Expression and Lymphangiogenesis by miR-195-3p in Oral Squamous Cell Carcinoma

  2018cited by this paper
• Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

  2018cited by this paper
• Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study

  2018cited by this paper
• A guide to chemokines and their receptors

  2018cited by this paper
• Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

  2018cited by this paper
• CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer

  2018cited by this paper
• Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab

  2018cited by this paper
• STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

  2018cited by this paper
• A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade

  2018cited by this paper
• Crucial biological functions of CCL7 in cancer

  2018cited by this paper
• Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers

  2018cited by this paper
• Patterns of Response and Progression to Immunotherapy.

  2018cited by this paper
• Roles of the immune system in cancer: from tumor initiation to metastatic progression

  2018cited by this paper
• Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4

  2018cited by this paper
• Overexpression of CXCL2 inhibits cell proliferation and promotes apoptosis in hepatocellular carcinoma

  2018cited by this paper
• Identification of genes and pathways, including the CXCL2 axis, altered by DNA methylation in hepatocellular carcinoma

  2018cited by this paper
• Epithelial mesenchymal transition induced by the CXCL9/CXCR3 axis through AKT activation promotes invasion and metastasis in tongue squamous cell carcinoma.

  2017cited by this paper
• Loss of PTEN Is Associated with Resistance to Anti‐PD‐1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma

  2017cited by this paper
• Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update

  2017cited by this paper
• Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma

  2017cited by this paper
• Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer

  2017cited by this paper
• IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade

  2017cited by this paper
• Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

  2017cited by this paper
• A CCL8 gradient drives breast cancer cell dissemination

  2016cited by this paper
• CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer

  2016cited by this paper
• Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade

  2016cited by this paper
• Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

  2016cited by this paper
• Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.

  2016cited by this paper
• CCL3 promotes angiogenesis by dysregulation of miR-374b/ VEGF-A axis in human osteosarcoma cells

  2015cited by this paper
• The future of immune checkpoint therapy

  2015cited by this paper
• Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

  2015cited by this paper
• Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

  2015cited by this paper
• New insights into the mechanism of action of immune checkpoint antibodies

  2014cited by this paper
• Classification of current anticancer immunotherapies

  2014cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014cited by this paper
• Tertiary lymphoid structures in cancer and beyond.

  2014cited by this paper
• Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression.

  2014cited by this paper
• Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma.

  2014cited by this paper
• CX3CL1 at the crossroad of EGF signals

  2013cited by this paper
• Identification and profiling of CXCR3–CXCR4 chemokine receptor heteromer complexes

  2013cited by this paper
• Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

  2013cited by this paper
• Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

  2013cited by this paper
• Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

  2013cited by this paper
• An immune-active tumor microenvironment favors clinical response to ipilimumab

  2012cited by this paper
• The immune contexture in human tumours: impact on clinical outcome

  2012cited by this paper
• Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells.

  2011cited by this paper
• Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.

  2009cited by this paper
• Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma

  2008cited by this paper
• Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

  2007cited by this paper
• Role of chemokines in tumor growth.

  2007cited by this paper
• Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer.

  2006cited by this paper
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

  2004cited by this paper
• Cancer and the chemokine network

  2004cited by this paper
• Chemokine receptor homo‐ or heterodimerization activates distinct signaling pathways

  2001cited by this paper
• The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization of its receptor CCR2.

  1999cited by this paper

• KMT2D deficiency potentiates antitumor immunity and sensitizes immune checkpoint blockade in urologic cancers

  2025cites this paper
• Prognostic Implications of Chemokine Signaling Pathway Mutations for Immune Checkpoint Inhibitor Therapy in Colon Adenocarcinoma

  2025cites this paper
• Multi-Omics Tumor Immunogenicity Score Predicts Immunotherapy Outcome and Survival

  2025cites this paper
• CCL20 in the tumor microenvironment: implications for cancer progression and therapeutic approaches

  2025cites this paper
• The cation channel Trpa1 and chemokine Cxcl1 mediate axonal degeneration in spared nerve injury–induced neuropathic pain

  2025cites this paper
• Chemokines: humble yet mighty players in the tumour microenvironment

  2025cites this paper
• Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma

  2024cites this paper
• Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma

  2023cites this paper
• Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

  2023cites this paper
• Bioinformatic analysis of immune-related transcriptome affected by IFIT1 gene in childhood systemic lupus erythematosus

  2023cites this paper
• ANGPTL2 promotes immune checkpoint inhibitor-related murine autoimmune myocarditis

  2023cites this paper
• Cutting-Edge Platforms for Analysis of Immune Cells in the Hepatic Microenvironment—Focus on Tumor-Associated Macrophages in Hepatocellular Carcinoma

  2022cites this paper
• Systematic Analysis of Chemokines Reveals CCL18 is a Prognostic Biomarker in Glioblastoma

  2022cites this paper
• Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy

  2022cites this paper
• Downregulation of SEPTIN5 inhibits prostate cancer progression by increasing CD8+ T cell infiltration

  2022cites this paper
• Expression of CX3CL1 and CCL28 in Spinal Metastases of Lung Adenocarcinoma and Their Correlation with Clinical Features and Prognosis

  2022cites this paper
• Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma

  2021cites this paper
• Correlation of Tim-3 expression with chemokine levels for predicting the prognosis of patients with glioblastoma.

  2021cites this paper
• Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies.

  2021cites this paper
• Systematic Analyses of a Chemokine Family-Based Risk Model Predicting Clinical Outcome and Immunotherapy Response in Lung Adenocarcinoma

  2021cites this paper
• NT5DC2 knockdown inhibits colorectal carcinoma progression by repressing metastasis, angiogenesis and tumor-associated macrophage recruitment: A mechanism involving VEGF signaling.

  2020cites this paper